Evidence map›Paper›PMID 38467980›Full record

ArticleAdvances in experimental medicine and biology2024

TCR Signals Controlling Adaptive Immunity against Toxoplasma and Cancer.

Masaaki Okamoto, Masahiro Yamamoto

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Masaaki OkamotoDepartment of Immunoparasitology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Masahiro YamamotoDepartment of Immunoparasitology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan. myamamoto@biken.osaka-u.ac.jp.
Osaka University · JPOsaka University of Pharmaceutical Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cells play a crucial role in adaptive immunity by recognizing and eliminating foreign pathogens and abnormal cells such as cancer cells. T cell receptor (TCR), which is expressed on the surface of T cells, recognizes and binds to specific antigens presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells (APCs). This activation process leads to the proliferation and differentiation of T cells, allowing them to carry out their specific immune response functions. This chapter outlines the TCR signaling pathways that are common to different T cell subsets, as well as the recently elucidated TCR signaling pathway specific to CD8

Indexed as

NeoplasmsToxoplasmaAdaptive ImmunityCD8-Positive T-LymphocytesReceptors, Antigen, T-CellT-Lymphocyte SubsetsReceptors, Antigen, T-CellCD8+ T cellsPLCβ4TCR signalingToxoplasmaTumor immunity

Identifiers

PMID38467980
OpenAlexW4392711576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.